EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023

by EpicentRx | Nov 6, 2023 | 2023, Press Releases

TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ — EpicentRx, Inc. (“EpicentRx”), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations...

No “Fall” in Activity for EpicentRx After Summer

by EpicentRx | Nov 1, 2023 | Company Updates

A busy Fall “leaves” little to no downtime for EpicentRx Summer slowdown? What summer slowdown? EpicentRx kicked off the Fall season in high gear with continuing preparations for the start of a large Phase 2b follow on study called KEVLARx with nibrozetone (RRx-001)...

Partnering with EpicentRx

by EpicentRx | Oct 19, 2023 | Media

“You are only as good as the company you keep” also applies to therapeutics like AdAPT-001 – EpicentRx

by EpicentRx | Oct 17, 2023 | Media

Oncolytic Virotherapy Summit 2023

by EpicentRx | Sep 25, 2023 | Conferences

December 2023; Boston, MA Oral Presentation: Evaluating the Advantages & Hurdles of Intratumoral Delivery of Oncolytic Viruses